Galmed Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary

Eocene

08/11/2021 14:32

* Galmed Pharmaceuticals Ltd  GLMD.OQ  reported a quarterly
adjusted loss of 31 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 36 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Galmed Pharmaceuticals Ltd's reported EPS for the quarter was
a loss of 31 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Galmed Pharmaceuticals Ltd shares had risen by 0.4% this
quarter and lost 10.0% so far this year.
* The company reported a quarterly loss of $7.71 million.
* Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $20.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 8 at 02:32 p.m.
 ​All figures in US dollars unless otherwise stated